CCL19 and Stroke: Compared with those in the AAV-TIE2-siRNA-NC group, mice treated with AAV-TIE2-siRNA-Ccl19 exhibited significant improvements in neurological deficit scores (Fig. 6F) and improved performance, including a reduced number of foot faults in the grid-walking test on day 4, 7, and 14 after stroke (Fig. 6G).